Karl J. Aichberger

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML

Karl J. Aichberger, Susanne Herndlhofer, G. Schernthaner et al. · American Journal of Hematology · 2011 · 300 citations

Medicine, Hematology, Pharmacology +13

TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms

Angela G. Fleischman, Karl J. Aichberger, Samuel B. Luty et al. · Blood · 2011 · 287 citations · Full text

Veterinary Medicine, Hematology, Immunology +13

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides

Karl J. Aichberger, Matthias Mayerhofer, Maria‐Theresa Krauth et al. · Blood · 2004 · 252 citations · Full text

Medicine, Molecular Biology, Oncology +12

PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects

Karoline V. Gleixner, Matthias Mayerhofer, Karl J. Aichberger et al. · Blood · 2005 · 247 citations · Full text

Medicine, Cancer Biology, Pharmacology +12

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

Jeffrey Tyner, Thomas G.P. Bumm, Jutta Deininger et al. · Blood · 2010 · 236 citations · Full text

Medicine, Hematology, Pharmacology +17